Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
238.095356946
InChI
InChI=1S/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)
InChI Key
InChIKey=WKGXYQFOCVYPAC-UHFFFAOYSA-N
IUPAC Name
3-(carbamoyloxy)-2-phenylpropyl carbamate
Traditional IUPAC Name
felbamate
SMILES
NC(=O)OCC(COC(N)=O)C1=CC=CC=C1
Độ hòa tan
Slightly soluble in water
pKa (strongest acidic)
14.98
Refractivity
59.59 m3·mol-1
Dược Lực Học :
Felbamate is an antiepileptic indicated as monotherapy or as an adjunct to other anticonvulsants for the treatment of partial seizures resulting from epilepsy. Receptor-binding studies in vitro indicate that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding, and is devoid of activity at the MK-801 receptor binding site of the NMDA receptor-ionophore complex. However, felbamate does interact as an antagonist at the strychnine-insensitive glycine recognition site of the NMDA receptor-ionophore complex.
Cơ Chế Tác Dụng :
Felbamate is an anticonvulsant drug used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.
The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. In vitro receptor binding studies suggest that felbamate may be an antagonist at the strychnine-insensitive glycine-recognition site of the N-methyl-D-aspartate (NMDA) receptor-ionophore complex. Antagonism of the NMDA receptor glycine binding site may block the effects of the excitatory amino acids and suppress seizure activity. Animal studies indicate that felbamate may increase the seizure threshold and may decrease seizure spread. It is also indicated that felbamate has weak inhibitory effects on GABA-receptor binding, benzodiazepine receptor binding.
Dược Động Học :
▧ Absorption :
>90%
▧ Volume of Distribution :
* 756±82 mL/kg
▧ Protein binding :
20-36%
▧ Metabolism :
Hepatic
▧ Half Life :
20-23 hours
▧ Clearance :
* 26 +/- 3 mL/hr/kg [single 1200 mg dose]
* 30 +/- 8 mL/hr/kg [multiple daily doses of 3600 mg]
Độc Tính :
LD50=5000 mg/kg (Orally in rats)
Chỉ Định :
For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
Tương Tác Thuốc :
-
Carbamazepine
Decreased effect of both products
-
Ethotoin
Increased phenytoin levels and decreased felbamate levels
-
Fosphenytoin
Increased phenytoin levels and decreased felbamate levels
-
Mephenytoin
Increased phenytoin levels and decreased felbamate levels
-
Phenobarbital
Felbamate increases the effect and toxicity of phenobarbital/primidone
-
Phenytoin
Increased phenytoin levels and decreased felbamate levels
-
Primidone
Felbamate may increase the effect and toxicity of primidone.
-
Quinupristin
This combination presents an increased risk of toxicity
-
Telithromycin
Telithromycin may reduce clearance of Felbamate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felbamate if Telithromycin is initiated, discontinued or dose changed.
-
Triprolidine
The CNS depressants, Triprolidine and Felbamate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
-
Ulipristal
Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy.
-
Valproic Acid
Felbamate, a CYP2C19 inhibitor, may decrease the metabolism of Valproic acid, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Felbamate is initiated, discontinued or dose changed.
-
Voriconazole
Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felbamate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felbamate if voriconazole is initiated, discontinued or dose changed.
Liều Lượng & Cách Dùng :
Suspension - Oral
Tablet - Oral
Dữ Kiện Thương Mại
Giá thị trường
-
Giá bán buôn : USD >1.43
Đơn vị tính : ml
-
Giá bán buôn : USD >2.71
Đơn vị tính : tablet
-
Giá bán buôn : USD >3.1
Đơn vị tính : tablet
Nhà Sản Xuất
-
Sản phẩm biệt dược : Felbamyl
-
Sản phẩm biệt dược : Felbatol
-
Sản phẩm biệt dược : Taloxa
Tài Liệu Tham Khảo Thêm
National Drug Code Directory